Search results for "cost effectiveness"

showing 10 items of 115 documents

PIN31: THE COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS) VS. INTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC HE…

2003

medicine.medical_specialtyCost effectivenessbusiness.industryHealth PolicyRibavirinPublic Health Environmental and Occupational HealthGastroenterologychemistry.chemical_compoundchemistryChronic hepatitisInternal medicinemedicinebusinessInterferon alfamedicine.drugPeginterferon alfa-2aValue in Health
researchProduct

Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C

2003

Background: Peginterferon α-2b plus ribavirin therapy in previously untreated patients with chronic hepatitis C yields the highest sustained virological response rates of any treatment strategy but is expensive. Aims: To estimate the cost effectiveness of treatment with peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of patients with chronic hepatitis C. Methods: Individual patient level data from a randomised clinical trial with peginterferon plus ribavirin were applied to a previously published and validated Markov model to project lifelong clinical outcomes. Quality of life and economic estimates were based on German patient data. We u…

medicine.medical_specialtyCost effectivenessbusiness.industryRibavirinGastroenterologyvirus diseasesAlpha interferonHepatitis CWirtschaftswissenschaftenmedicine.diseaseGastroenterologySurgeryQuality-adjusted life yearClinical trialchemistry.chemical_compoundchemistryInternal medicinemedicinebusinessViral loadInterferon alfamedicine.drug
researchProduct

Effektivität einer universellen Varizellen-Schutzimpfung in Deutschland: Eine epidemiologische und gesundheitsökonomische Analyse

2006

Varicella is a highly contagious viral disease which mainly affects young children and usually is perceived as infection with a mild disease course. However, there is increasing evidence indicating that the morbidity and mortality as well as the economic impact associated with varicella are significant. While universal childhood vaccination against varicella is currently not recommended in Germany, the availability of safe and efficacious vaccines offers the opportunity for preventive intervention. Detailed and reliable data on the consequences of varicella and the possible impact of a universal vaccination program are missing to date for Germany. In order to generate this information, we c…

medicine.medical_specialtyCost effectivenessbusiness.industryvirusesvirus diseasesChildhood vaccinationVaricella vaccinationVirologyVaccinationEnvironmental healthPediatrics Perinatology and Child HealthEpidemiologymedicineEconomic analysisViral diseaseEconomic impact analysisbusinessKlinische Pädiatrie
researchProduct

Cost-effectiveness and cost-utility analysis of the treatment of emotional disorders in primary care: psicap clinical trial. description of the sub-s…

2018

Introduction: In the primary care (PC) setting in Spain, the prevalence of emotional disorders (EDs) such as anxiety, depression and somatoform disorder is high. In PC patients, these disorders are not always managed in accordance with the recommendations provided by clinical practice guidelines, resulting in major direct and indirect economic costs and suboptimal treatment outcomes. The aim is to analyze and compare the cost-effectiveness and cost-utility of group-based psychological therapy versus treatment as usual (TAU). Methods: Multicenter, randomized controlled trial involving 300 patients recruited from PC centers in Madrid, Spain, with symptoms or possible diagnosis of anxiety, moo…

medicine.medical_specialtyCost effectivenesslcsh:BF1-990QALYslaw.inventionprimary care03 medical and health sciencesIndirect costs0302 clinical medicineRandomized controlled triallawmedicinePsychologyClinical Study Protocol030212 general & internal medicinecost-utilityGeneral PsychologyCost–utility analysisEmocionstransdiagnostic cognitive-behavioral therapy030227 psychiatryPatient Health QuestionnaireClinical triallcsh:PsychologyMoodemotional disordersPhysical therapyAnxietymedicine.symptomPsychology
researchProduct

HCV eradication: a duty of the State, an option for the individual

2020

In recent years, the debate on ethical issues related to hepatitis C virus therapies has been focused on the problem of drug prices and access to therapies. Nonetheless, the goal of hepatitis C virus eradication set by the World Health Organization in 2016 is raising new ethical issues, since governments are faced with a new challenge: reaching through screening, diagnosis and treatment a large amount of subjects with undiagnosed hepatitis C infection. National governments, especially high-income countries with a Welfare State, are compelled to provide access to therapies, but also to involve those who are still unaware of their disease status. Since people cannot be forced but should be gu…

medicine.medical_specialtyCost effectivenessmedia_common.quotation_subjectHepatitis C virusmedicine.disease_causeSettore MED/02 - Storia Della Medicina03 medical and health sciences0302 clinical medicineState (polity)Settore MED/43 - Medicina Legalemedicinehcv030212 general & internal medicineEthicIntensive care medicineDutyAutonomymedia_commonEradicationEthical issuesbusiness.industryWelfare stateHepatitis Cmedicine.diseaseCost-effectivenessbusinessAutonomy
researchProduct

Cost effectiveness analysis of childhood obesity primary prevention programmes: a systematic review

2022

Background. Childhood obesity is associated with enormous health consequences and costs to society. This study aims to systematically review the studies on Cost Effectiveness Analysis (CEA) of primary prevention programmes of childhood obesity, discussing the gaps and providing recommendations for future research. Methods. All the studies on the cost effectiveness evaluation of primary prevention of obesity among children were included. Studies were retrieved from MEDLINE and Google Scholar, up to 31st March 2012, with only English language papers being eligible. The quality of the retrieved studies was evaluated by using the Drummond scale. Re…

medicine.medical_specialtyCost effectivenessprimary preventionAlternative medicineMEDLINEsystemic reviewOverweightSettore MED/42 - Igiene Generale E ApplicataChildhood obesityIntervention (counseling)medicineoverweightcost-effectivenesslcsh:R5-920business.industrylcsh:Public aspects of medicinelcsh:RA1-1270Cost-effectiveness analysismedicine.diseaseScale (social sciences)Family medicinePhysical therapymedicine.symptombusinesslcsh:Medicine (General)childhood obesitycost-effectiveness childhood obesity overweight primary prevention systemic reviewEpidemiology Biostatistics and Public Health
researchProduct

Closed Incision Negative Pressure Therapy Achieves Better Outcome Than Standard Wound Care: Clinical Outcome and Cost-Effectiveness Analysis in Open …

2020

BackgroundSurgical site infections (SSIs) and surgical site occurrences (SSOs) are frequent post-operative complications that are dependent on the presence of different risk factors. The use of closed incision negative pressure therapy (ciNPT) is considered a measure by the WHO guidelines for prevention of SSIs. The prevention of SSOs is an extremely important issue in the ventral hernia repair (VHR) surgical field. SSO onset not only affects the patient's quality of life, but can also cause the onset of life-threatening conditions that may require re-hospitalization, re-intervention and often mesh removal. Such outcome can become extremely costly, contributing to increased health care cost…

medicine.medical_specialtyCost effectivenessventral hernia repair030204 cardiovascular system & hematology03 medical and health sciencesWound care0302 clinical medicineQuality of lifeEpidemiologyMedicineguidelinescost-effectivenesssurgical site occurrencesbusiness.industryMedical recordGeneral Engineeringsurgical site infectionsCost-effectiveness analysisabdominal surgeryQuality ImprovementSurgeryRelative riskGeneral Surgeryoutcomeclosed incision negative pressure therapyPreventive Medicinebusiness030217 neurology & neurosurgeryAbdominal surgery
researchProduct

Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma

2020

Background: Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ quality of life and increased healthcare spending. Objectives: To assess the clinical and economic impact of switching from omalizumab (OMA) to mepolizumab (MEP) in patients eligible for both biologics but not optimally controlled with OMA. Methods: Uncontrolled patients referred to 6 asthma clinics in south of Italy switched from OMA to MEP, were enrolled and followed-up to Jan 2020. Clinical information included blood eosinophil count, asthma control test (ACT), pulmonary function, IgE, exhaled nitric oxide (FeNO), OCS intake, drugs, exacerbations/hospitalizations, …

medicine.medical_specialtyExacerbationCost effectivenessbusiness.industryOmalizumabmedicine.diseaseDiscontinuationPulmonary function testingInternal medicineExhaled nitric oxidemedicinebusinessMepolizumabmedicine.drugAsthmaEthics and economics
researchProduct

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy

2016

ABSTRACT Objective: To evaluate the cost-effectiveness of bedaquiline plus background drug regimens (BR) for multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) in Italy. Methods: A Markov model was adapted to the Italian setting to estimate the incremental cost-effectiveness ratio (ICER) of bedaquiline plus BR (BBR) versus BR in the treatment of MDR-TB and XDR-TB over 10 years, from both the National Health Service (NHS) and societal perspective. Cost-effectiveness was evaluated in terms of life-years gained (LYG). Clinical data were sourced from trials; resource consumption for compared treatments was modelled according to advice from an expert c…

medicine.medical_specialtyPediatricsTuberculosisCost effectivenessBedaquilinelcsh:Business03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSocietal perspectivemedicineOriginal Research Article030212 general & internal medicineResource consumptionSensitivity analysescost-effectivenessDisease treatmenthealth care economics and organizationsbusiness.industrylcsh:Public aspects of medicinelcsh:RA1-1270medicine.diseaseNational health serviceMDR tuberculosis030228 respiratory systemchemistryItalyEmergency medicineXDR tuberculosisOriginal ArticleBedaquilinebusinesslcsh:HF5001-6182Journal of Market Access & Health Policy
researchProduct

Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.

2015

Objective:Across Italy up to 7.3% of the population is infected with hepatitis C virus (HCV), with long-term complications resulting in high medical costs and significant morbidity and mortality. Current treatment options have limitations due to side effects, interferon intolerability and ineligibility, long treatment durations and low sustained virological response (SVR) rates, especially for the most severe patients). Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir, administered with ribavirin (RBV) and with or without pegylated interferon (PEG-INF), resulted in >90% SVR across treatment-naïve (TN) genotype (GT) 1-6 patients. It is also t…

medicine.medical_specialtySofosbuvirGenotypeCost effectivenessHepatitis C virusCost-Benefit AnalysisAlpha interferonmedicine.disease_causeGastroenterologyPolyethylene GlycolAntiviral AgentsSeverity of Illness IndexTelaprevirTelaprevirPolyethylene Glycolschemistry.chemical_compoundPegylated interferonBoceprevirInternal medicineQuality-Adjusted Life YearRibavirinmedicineCost-effectiveness analysiHumansCost-Benefit AnalysiAntiviral AgentBoceprevirbusiness.industryHealth PolicyRibavirinInterferon-alphaMarkov ChainHepatitis C ChronicPatient Acceptance of Health CareVirologyChronic hepatitis C infectionMarkov ChainschemistryItalyDrug Therapy CombinationQuality-Adjusted Life YearsSofosbuvirbusinessmedicine.drugHumanJournal of medical economics
researchProduct